NEXT WEEK FOMC minutes , whole market will be falling waiting for it, CLDX could touch $26
okkkaaayyyyy but if you are real then answer this
" 'Generally' well tolerated" is a major red flag. Toxicity is high with very little efficacy data shown. Sell now before this drops to $3-4. Rebuy after the sell off for Relistor run up. Don't be caught holding this.
70K was AH retailer ??? and why would anyone sell and why wouldn't buyers move in on these cheap prices if indeed this was good news 70K x $5.40 avg = $500K
Investment bankers did not agree for a price for secondary because they couldn't scam the investors.
Two days before bad poster = bad phase II data they couldn't fix the price of secondary. Now that we know price will be between $4 and $5 secondary could be between $3 and $4
Dr Alex Baker there is another issue with PGNX which is Relistor
Latest buzz on the street is that FDA did not approve Relistor. Since there are CV issues with Relistor and others in this class the FDA has called a meeting to discuss the class. AZN will be there as well to discuss. AZN position is NKTR 118 is proven safe. The trial was approved by the FDA. There is a major difference between pills and injection. Sales for pills are far greater than drugs delivered by injection. Generally pills are safer. I don't expect NKTR 118 to get reviewed faster but we may see if it will gets approved at all in March's FDA meeting. Some were speculating if the FDA will approve and require additional testing. The data AZN has submitted is enough. The data is night and day different between Relistor and NKTR 118. Relistor has documented cases of CV issues. There is no additional data which SLXP or PGNX can provide on the safety of Relistor. NKTR 118 is superior in safety and we have the data to prove it.
you will soon find out if i was right or not...... unfortunately due to copyright , i can't post it, otherwise i would have...
Jury could award victims the market cap lost $700M ~ $1 Billion, where will SRPT produce this is money from , from their rear ?
as per the lawsuit
shareholder class actions, announces the filing of the first securities class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta"), as filed in the United States District Court for the District of Massachusetts. The complaint alleges violations of federal securities laws; more specifically, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of materially false or misleading statements surrounding its disease-modifying drug, eteplirsen, which is used in the treatment of Duchenne muscular dystrophy or DMD. These statements had the effect of artificially inflating the market price of Sarepta's stock during the period of July 24, 2013 through and including November 12, 2013 (the "Class Period").
During this Class Period, it is alleged that Sarepta issued a series of multiple statements concerning, among other things: (1) the prospects of the Food and Drug Administration's ("FDA") acceptance for consideration of a New Drug Application ("NDA") for eteplirsen based on Sarepta's Phase IIb study data set, and (2) the significance of that data set. However, during a meeting on November 12, 2013, the FDA informed Sarepta that its announced, anticipated NDA filing for eteplirsen was premature. On this negative news, Sarepta's stock price fell $23.40, a decline of 64%, from its closing price of $36.56 per share on November 11, 2013, to $13.16 per share on November 12, 2013, on extraordinary volume
laugh all you can which proves real idi0t is you, from $12.90 it went to $9.80 in 4 trading days.... are you on pills ?
broke below $6 , where are those losers who said it won't drop below $6
could we see $20
pipe piper arnh0le pipe piper swineh0le pipe piper bullh0le pipe piper longh0le
Pfizer lung-cancer drug fails in two Phase III studies
Pfizer's Dacomitinib drug has failed in two Phase III trials of patients with refractory advanced non-small cell lung cancer.In the ARCHER 1009 trial, which included patients previously treated with chemotherapy, Dacomitinib did not significantly improve progression-free survival (PFS) when compared with the Erlotinib (Tarceva) drug.In the second study, Dacomitinib was unable to lengthen survival vs a placebo.A third Phase III trial is assessing Dacomitinib in a different patient population, with the results expected in 2015
How about dummy NeuVax where everyone knows who is Arnh0le and what tricks he has trying to pull from his hat or under pants ?!!!
Sentiment: Strong Sell
Gale CEO has a history of playing around
pipe piper pipe piper